<DOC>
	<DOC>NCT01716806</DOC>
	<brief_summary>This is an open-label, multicenter, phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin as a single-agent (Part A) and in combination with dacarbazine (Part B), bendamustine (Part C), or nivolumab (Part D) in front-line therapy of HL in adults age 60 and above.</brief_summary>
	<brief_title>A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Histopathologicallyconfirmed diagnosis of classical Hodgkin lymphoma Ineligible for or have declined initial conventional combination chemotherapy Measurable disease of at least 1.5 cm as documented by radiographic technique ECOG performance status less than or equal to 3 Symptomatic neurologic disease compromising instrumental activities of daily living or requiring medication Concurrent use of other investigational agents Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed 4 weeks prior to first dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Hodgkin Disease</keyword>
	<keyword>Antigens, CD30</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>monomethylauristatin E</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>